Who
Tina Susan Nova
Director
Company insider
Files Form 4 as: Director, Aurinia Pharmaceuticals; Director, Azenta; Executive Chairperson, Exagen; Director, Arena Pharmaceuticals; President, CLIA U.S., Veracyte; Director, Opgen; Director, NanoString Technologies; Director, Adamis Pharmaceuticals.
In numbers
- Trades disclosed
- 174
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $10.4M
- Companies
- 10
- Companies where not an officer
- 7
- First trade
- 28 Jul 2006
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,931 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,931 at $0.00 | filing |
| 6 Feb 2026filed 6 Feb 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $158K5,663 at $27.85 | filing |
| 6 Feb 2026filed 6 Feb 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $158K5,663 at $27.85 | filing |
| 10 Jun 2025filed 12 Jun 2025 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 16 May 2025filed 16 May 2025 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —63,724 at $0.00 | filing |
| 7 Feb 2025filed 11 Feb 2025 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $211K4,040 at $52.32 | filing |
| 10 Jun 2024filed 12 Jun 2024 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 12 Feb 2024filed 13 Feb 2024 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | $163K2,465 at $65.93 | filing |
| 15 Jun 2023filed 20 Jun 2023 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 13 Feb 2023filed 15 Feb 2023 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | —3,604 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | XGN Exagenoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —4,800 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —7,202 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticals | SEC FORM 4 Code J | —17,776 | filing |
| 11 Mar 2022filed 11 Mar 2022 | Arena Pharmaceuticals | SEC FORM 4 Code J | —3,067 | filing |
News
No headline names them, or the companies they trade most, lately.